Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403937 | 1.00 | TAS1R3 (0.51) | TAS1R3TAS1R1ERAP2LNPEPALDH1A1 | |
| SCHEMBL9902468 | 1.00 | TAS1R3 (0.51) | TAS1R3TAS1R1ERAP2LNPEPALDH1A1 | |
| SCHEMBL26604248 | 0.88 | TAS1R3 (0.55) | TAS1R3TAS1R1ERAP2LNPEPALDH1A1 | |
| SCHEMBL2873360 | 0.86 | CA2 (0.56) | ALDH1A1GAAPKMCA2CA1 | |
| SCHEMBL9925842 | 0.85 | CA2 (0.43) | ALDH1A1GAAPKMCA2CA1 | |
| SCHEMBL402028 | 0.85 | CA2 (0.43) | ALDH1A1GAAPKMCA2CA1 | |
| SCHEMBL25031639 | 0.83 | ALDH1A1 (0.51) | TAS1R3TAS1R1ALDH1A1GAAPKM | |
| SCHEMBL12837671 | 0.82 | CA2 (0.43) | TAS1R3TAS1R1ALDH1A1GAAPKM | |
| SCHEMBL403938 | 0.75 | CA2 (0.44) | TAS1R3TAS1R1ERAP2ALDH1A1GAA | |
| SCHEMBL27643333 | 0.75 | CA2 (0.46) | ERAP2LNPEPALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| CN-102267924-A | Antibacterial agent | — | 2011-12-07 | — | — | CN | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| CN-1777577-B | Antibacterial agent | CHIRON CORP | 2011-07-06 | — | — | CN | disclosed |
| EP-2295402-A2 | Antibacterial agents | The University of Washington (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| CN-1777577-A | Antibacterial agent | CHIRON CORP (US) | 2006-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | TAS1R3 4169/4885TAS1R1 3477/4885ERAP2 1084/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | TAS1R3 4169/4885TAS1R1 3477/4885ERAP2 1084/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | TAS1R3 4169/4885TAS1R1 3477/4885ERAP2 1084/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | TAS1R3 4169/4885TAS1R1 3477/4885ERAP2 1084/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | TAS1R3 4169/4885TAS1R1 3477/4885ERAP2 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.